Omega Therapeutics IPO Presentation Deck

Tumor inhibition by targeting and controlling cMYC MYC • Is an essential master regulator of cell growth • Regulates 15-20% of entire human genome Signal transduction Cell cycle Metabolism Wat signaling pathway Translation Cyclins CDK CDKis GLUTI LOH,GLS elf-2a Transcription E2F Myc MILHI BINI DNA repair MYC dysregulation Protein biosynthesis mRNA tRNA Ribosomal biogenesis Let 7 family 0301 integrin cdc42 Other target Others MicroRNAs Cell adhension and cytoskeleton Is present in >50% of human cancers Is associated w/ poor prognosis and mortality Chen, et al., Signal Transduction and Targeted Therapy (2018) 3:5 ©2021 Omega Therapeutics, Inc. Tumor Volume (mm³) 1000₁ 800 600- 400 200 Statistically significant inhibition of HCC tumor growth by direct targeting of MYC at the pre- transcriptional level Negative Control OEC Candidate Day *HH 10 *Statistically significant vs negative control, t-test p<0.05 starting on day 6 Arrows denote dosing days

View entire presentation